Abstract:Uveal melanoma (UM) is a highly metastatic cancer with resistance to immunotherapy. The present study aimed to identify novel feature genes and molecular mechanisms in UM through analysis of single‐cell sequencing data. For this purpose, data were downloaded from The Cancer Genome Atlas and National Center for Biotechnology Information Gene Expression Omnibus public databases. The statistical analysis function of the CellPhoneDB software package was used to analyze the ligand‐receptor relationships of the feature genes. The Metascape database was used to perform the functional annotation of notable gene sets. The randomForestSRC package and random survival forest algorithm were applied to screen feature genes. The CIBERSORT algorithm was used to analyze the RNA‐sequencing data and infer the relative proportions of the 22 immune‐infiltrating cell types. In vitro , small interfering RNAs were used to knockdown the expression of target genes in C918 cells. The migration capability and viability of these cells were then assessed by gap closure and Cell Counting Kit‐8 assays. In total, 13 single‐cell sample subtypes were clustered by t‐distributed Stochastic Neighbor Embedding and annotated by the R package, SingleR, into 7 cell categories: Tissue stem cells, epithelial cells, fibroblasts, macrophages, natural killer cells, neurons and endothelial cells. The interactions in NK cells|Endothelial cells, Neurons|Endothelial cells, CD74_APP, and SPP1_PTGER4 were more significant than those in the other subsets. T‐Box transcription factor 2, tropomyosin 4, plexin D1 ( PLXND1 ), G protein subunit α I2 ( GNAI2 ) and SEC14‐like lipid binding 1 were identified as the feature genes in UM. These marker genes were found to be significantly enriched in pathways such as vasculature development, focal adhesion and cell adhesion molecule binding. Significant correlations were observed between key genes and immune cells as well as immune factors. Relationships were also observed between the expression levels of the key genes and multiple disease‐related genes. Knockdown of PLXND1 and GNAI2 expression led to significantly lower viability and gap closure rates of C918 cells. Therefore, the results of the present study uncovered cell communication between endothelial cells and other cell types, identified innovative key genes and provided potential targets of gene therapy in UM.

Identification of targetable epigenetic vulnerabilities in uveal melanoma

Abstract 4581: Identifying class 1 HDACs as a vulnerability for aggressive uveal melanoma

Identifying biomarkers and novel therapeutic targets in uveal melanoma

Development of New Therapeutic Options for the Treatment of Uveal Melanoma

Co-Targeting of DTYMK and PARP1 as a Potential Therapeutic Approach in Uveal Melanoma

Emerging therapeutic strategies for metastatic uveal melanoma: Targeting driver mutations

Recent Advances in Molecular and Genetic Research on Uveal Melanoma

Uveal Melanoma: Progress in Molecular Biology and Therapeutics.

[Uveal Melanoma: Molecular and Genetic Mechanisms of Development and Therapeutic Approaches]

Uveal Melanoma: Molecular and Genetic Mechanisms of Development and Therapeutic Approaches

Role of Epigenetics in Uveal Melanoma

The Prognostic Landscape of Adaptive Immune Resistance Signatures and Infiltrating Immune Cells in the Tumor Microenvironment of Uveal Melanoma.

Uveal melanoma: molecular-genetic mechanisms of arising and the therapeutic approaches

Identification of feature genes and molecular mechanisms involved in cell communication in uveal melanoma through analysis of single‐cell sequencing data

Single-cell RNA Sequencing Reveals Key Molecular Drivers and Immune Landscape in Uveal Melanoma: Implications for Targeted Therapy and Prognostic Modeling

Epigenetic therapy to enhance therapeutic effects of PD-1 inhibition in therapy-resistant melanoma

Prognostic Value of BAP1 Protein Expression in Uveal Melanoma

Uveal melanoma immunogenomics predict immunotherapy resistance and susceptibility

Molecular characterization of metastatic progression in patient derived xenograft models of malignant uveal melanoma

Regulation of epigenetic homeostasis in uveal melanoma and retinoblastoma

Ubiquitin–proteasome System-Targeted Therapy for Uveal Melanoma: What is the Evidence?